Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
The Oncologist
|
January 17, 2026
An FDA analysis of the association of tumor growth rate, overall survival and progression-free survival in patients with metastatic NSCLC
Justin N Malinou, Jiaxin Fan, Joyce Cheng, et al.
JAMA Oncology
|
August 4, 2022
A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria
David E Gerber, Harpreet Singh, Erin Larkins, et al.
Seminars in Oncology
|
November 5, 2018
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies
Shanthi Marur, Harpreet Singh, Pallavi Mishra-Kalyani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 10, 2024
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes
Erica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, et al.
The Oncologist
|
October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy
Erin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
The Oncologist
|
February 13, 2024
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
Jonathon Vallejo, Harpreet Singh, Erin Larkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival
Elizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
The Lancet. Oncology
|
March 8, 2024
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC
Luckson N Mathieu, Erin Larkins, Arup K Sinha, et al.
The Oncologist
|
May 24, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Erin Larkins, Gideon M Blumenthal, Weishi Yuan, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
The Oncologist
|
January 17, 2026
An FDA analysis of the association of tumor growth rate, overall survival and progression-free survival in patients with metastatic NSCLC
Justin N Malinou, Jiaxin Fan, Joyce Cheng, et al.
JAMA Oncology
|
August 4, 2022
A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria
David E Gerber, Harpreet Singh, Erin Larkins, et al.
Seminars in Oncology
|
November 5, 2018
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies
Shanthi Marur, Harpreet Singh, Pallavi Mishra-Kalyani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 10, 2024
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes
Erica G Horodniceanu, Tejaswi Datla, Meena N Murugappan, et al.
The Oncologist
|
October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy
Erin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
The Oncologist
|
February 13, 2024
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
Jonathon Vallejo, Harpreet Singh, Erin Larkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival
Elizabeth S Duke, Diana Bradford, Arup K Sinha, et al.
The Lancet. Oncology
|
March 8, 2024
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC
Luckson N Mathieu, Erin Larkins, Arup K Sinha, et al.
The Oncologist
|
May 24, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Erin Larkins, Gideon M Blumenthal, Weishi Yuan, et al.
Page
of 3